van den Berg, P. F.
Yousif, L. I.
Markousis-Mavrogenis, G.
Shi, C.
Bracun, V.
Tromp, J.
de Wit, S.
Appels, Y.
Screever, E. M.
Aboumsallem, J. P.
Ouwerkerk, W.
van Veldhuisen, D. J.
Silljé, H. H. W.
Voors, A. A.
de Boer, R. A.
Meijers, Wouter C.
Article History
Received: 17 November 2023
Accepted: 3 July 2024
First Online: 5 August 2024
Declarations
:
: The BIOSTAT-CHF study complied with the Declaration of Helsinki and was approved by national and local ethics committees (EudraCT 2010-020808-29; R&D Ref Number 2008-CA03; MREC Number 10/S1402/39).
: Not applicable.
: The UMCG, which employs several of the authors, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals Inc., Novo Nordisk, and Roche (outside the submitted work). RAdB has received research grants or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche (outside the submitted work). WCM has received speaker/ advisory board fees from Daiichi Sankyo and Novartis (outside the submitted work). All other authors declare that they have no competing interests.